Care Coordination Approaches to Learning Lupus Self-management (CALLS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Overview of Study Design. The Care-coordination Approach to Learning Lupus Self-Management (CALLS) study is a double arm, pre-post pilot designed to examine whether modeling and reinforcement from a lay patient navigator/care coordinator improves disease self-management, indicators of disease activity, health related quality of life (HRQOL), and 30-day readmission in SLE inpatient admissions. We will recruit 40 patients (20 questionnaires and phone sessions and 20 questionnaires only) with active SLE upon hospital admittance at the Medical University of South Carolina (MUSC). The lay patient navigator/care coordinator will be trained to deliver intervention content by twelve weekly telephone sessions carried out across the course of the study. All participants will be assessed using validated measures of patient reported outcomes at baseline, mid-intervention (6 weeks post-enrollment), and immediately following the intervention (12 weeks post-enrollment). Outcomes for patients who agree to phone sessions will be compared with the outcomes of patients who opt to participate in questionnaires only. The study will last 12 months with recruitment and enrollment over 6 months, 3 months for intervention delivery and 3 months for data analysis.
Study Population. The target population for this study will be SLE inpatient admissions at MUSC. There are approximately 35 SLE and Scleroderma hospital admissions each month, so it is expected that over a 3-month recruitment period, we will be able to recruit 40 participants (20 questionnaires and phone sessions and 20 questionnaires only).
Recruitment of Lay Patient Navigator/Care Coordinator The PI will identify a suitable lay patient navigator/care coordinator based on their maturity, emotional stability, and verbal communication skills. Suitable candidates will have at least a high school diploma or equivalency with at least one year of patient care experience in a health care facility; or a Certified Nursing Assistant; or successful completion of a Nursing Assistant or Medical Assistant course at an accredited institution or equivalent training; or EMT or Paramedic certification; or a Bachelor's degree. They will possess the ability to understand and implement a variety of detailed instructions in the execution of therapeutic procedures and the ability to make accurate physical observation of patients.
Recruitment of SLE patients Admitted SLE patients will be referred by their physician for participation in the study, who will provide a letter that will explain the study and provide participants a number to call if they have questions or concerns prior to agreeing to participate. Participants who indicate interest in the study will be immediately screened for eligibility, and if eligibility criteria are met, informed consent will be obtained. Once a patient has been consented, they will be randomized to membership in one of the two study arms. assigned to the intervention (complete questionnaires and phone sessions) or control (complete questionnaires only) arm, and the rest of the recruitment visit will include baseline self-report assessments and scheduling of phone sessions (if applicable).
Phone sessions: The CALLS program will focus on enhancing the health of SLE patients, with emphasis on patient empowerment and promoting proactive participation in health care. Recruitment and enrollment will occur on a rolling basis, and the program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation. The lay patient navigator/care coordinator will respond to individual patient needs by tailoring intervention content to personal requirements and facilitating care coordination and will be able to address insurance, financial, and logistical issues (e.g., transportation, appointment scheduling, child or elder care), while providing understandable health education that may lessen fears of SLE diagnosis and treatment. Lay patient navigator/care coordinator activities will be guided by frequent self-report assessments, which will help to identify patient concerns across multiple domains, triage patients to appropriate resources, and ultimately overcome barriers to health care. The lay patient navigator/care coordinator can use baseline data collected prior to phone sessions to describe preliminary patient themes (i.e., disease activity and damage, depression, medication adherence, communication with provider, patient engagement) and subsequent assessments can be used to track progress.
Data Collection Schedule. Study questionnaires were carefully chosen based on available evidence of previous validation and their ability to measure key elements of the study aims. The primary method of data collection will be face-to-face interview. All study visits will take place in an MUSC affiliated hospital, the Research Nexus or comparable private location on the campus of MUSC. Indicators of medication adherence will be extracted from the electronic medical records. Financial data will be extracted from the research data warehouse for historical and patient-specific data for cost effectiveness. The MUSC REDCap system will be used for data management.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hospital admission for SLE-related issue;
- clinical diagnosis of systemic lupus erythematosus (SLE) from a physician;
- 18 years of age or older;
- able to provide informed consent and take part in ongoing assessment/evaluation activities (self-reported questionnaires);
- able to commit to duration of study (3 months);
- able to communicate in English; and
- have an active phone line (landline or cell phone) for the duration of the study, if agreeing to phone sessions with the lay patient navigator/care coordinator.
Exclusion Criteria:
- cognitive impairment;
- acute decompensation of chronic conditions precluding participation;
- conditions that preclude participation in assessments (e.g. blindness or deafness); and
- terminal illness or life expectancy less than 6 months as evaluated by physician.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
complete questionnaires and phone sessions
|
The CALLS program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week.
The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving.
Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature.
Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation.
|
|
No Intervention: Control
complete questionnaires only
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Self-management measured using the Patient Activation Measure (PAM)
Time Frame: Baseline to post-intervention, at 12 weeks
|
The Patient Activation Measure (PAM) assesses an individual's knowledge, skill, and confidence for managing their health and healthcare.
Individuals who measure high on this assessment typically understand the importance of taking a proactive role in managing their health and have the skills and confidence to do so.
The PAM survey measures patients on a 0-100 scale and can segment patients into one of four activation levels along an empirically derived continuum, including "Believes Active Role Important", "Confidence and Knowledge to Take Action", "Taking Action", and "Staying Course Under Stress".
Each activation level reveals insight into an array of health-related characteristics, including attitudes, motivators, behaviors, and outcomes.
|
Baseline to post-intervention, at 12 weeks
|
|
Satisfaction in Quality of Life as assessed by the LUP-QOL (Lupus Quality of Life Questionnaire)
Time Frame: Baseline to post-intervention, at 12 weeks
|
Quality of life will be assessed by using The LUP-QOL (Lupus Quality of Life Questionnaire), which assesses areas of the participant's life that may be affected by lupus.
The score ranges from 0-100.
A score of '0' indicates the lowest quality of life, and a score of 100 indicates the best quality of life.
|
Baseline to post-intervention, at 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
30-day readmission
Time Frame: Baseline to post-intervention, at 12 weeks
|
Change in cost due to readmission.
Costs will include total charges associated with any healthcare encounters at the Medical University of South Carolina.
|
Baseline to post-intervention, at 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 00070647
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
NCT01551069CompletedCutaneous Lupus Erythematosus-Systemic Lupus Erythematosus
-
NCT06625671RecruitingSystemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
-
NCT06737380RecruitingSystemic Lupus Erythematosus | SLE | Systemic Lupus Erythematosus (SLE) | Lupus | Systemic Lupus Erthematosus
-
NCT07260877RecruitingSystemic Lupus Erythematosus | SLE | Cutaneous Lupus Erythematosus (CLE) | CLE | SLE (Systemic Lupus)
-
NCT07470957Not yet recruitingSystemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)
-
NCT07332481RecruitingSystemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)
-
NCT05411016Active, not recruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)
-
NCT07010835RecruitingSystemic Lupus Erythematosus (SLE)
-
NCT06530849RecruitingRefractory Systemic Lupus Erythematosus
Clinical Trials on CALLS
-
NCT05000099CompletedDepression | Anxiety | Aging | Social Isolation
-
NCT00624806CompletedSpinal Cord Injury
-
NCT01620827CompletedSubject Follow-up
-
NCT02162901Completed
-
NCT01406028CompletedIn Vitro Fertilization | Psychological Stress
-
NCT00888992CompletedSmoking Cessation
-
NCT05481593CompletedDisability Physical | Chronic Conditions, Multiple | Chronic Condition
-
NCT07154836Enrolling by invitation